ProfileGDS5678 / 1456042_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 79% 77% 83% 80% 80% 80% 82% 80% 81% 81% 81% 82% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5228279
GSM967853U87-EV human glioblastoma xenograft - Control 25.520779
GSM967854U87-EV human glioblastoma xenograft - Control 35.2665977
GSM967855U87-EV human glioblastoma xenograft - Control 46.2158483
GSM967856U87-EV human glioblastoma xenograft - Control 55.7193880
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.471680
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.5079780
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.9072782
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6561580
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7979681
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7224481
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9137381
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8649682
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.5155579